Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

Summary

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

Timeline

Start

2004-12

Primary completion

—

Completion

2007-01

Outcome

Missed primary endpoint

paper There was no significant difference between LY686017 and placebo as measured with the Liebowitz Social Anxiety scale (LSAS). PMID 20018493 ↗

Publications

• Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, Marek G. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010 Feb;20(2):80-7. doi: 10.1016/j.euroneuro.2009.10.005. Epub 2009 Dec 16.

Drugs

Indications